CABERGOLINE 0.5mg. IP

A dopamine agonist medicament that lowers high levels of prolactin hormone in the blood. (Karen J Tulloch, 2019) A potent and very long-acting inhibitor of prolactin secretion of puerperal lactation and in the treatment of hyperprolactinemic disorders. (C Ferrari, 1995) Ceases the brain from releasing the prolactin hormone from the pituitary gland. A prolactin-lowering drug, more effective and better tolerated than bromocriptine for the treatment of hyperprolactinemic amenorrhea. (V Pascal-Vigneron, 1995) An alternative drug in patients with hyperprolactinemia who have failed treatment with, or are intolerant of, other dopamine agonists such as bromocriptine. (C P Rains, 1995) Offers significant advantages over bromocriptine in the prevention or suppression of puerperal lactation. (C P Rains, 1995) A safe and effective pharmacologic option for the prevention of lactation and associated physical symptoms in non-breastfeeding women. (Karen J Tulloch, 2019) Normalizes prolactin levels, improves gonadal and sexual function and fertility in males with prolactinoma. (M De Rosa, 1998) More effective than bromocriptine in controlling symptoms associated with hormone excess normalizes serum prolactin levels and shrinks prolactinomas. (A Arduc, 2015) A beneficial agent for the treatment of menstrual irregularities in polycystic ovary syndrome patients. (Azam Ghaneei, 2015) Significantly more effective than bromocriptine in suppressing prolactin secretion and restoring the menstrual cycle in female patients with idiopathic hyperprolactinemia. (Johan Verhelst, 1999) More effective than bromocriptine in the resolution of amenorrhea/oligomenorrhea and galactorrhea. (Nicolás Triantafilo, 2016)